Reshma Rangwala
EVP & Chief Medical Officer · Karyopharm Therapeutics Inc.
- 2025
- May 15, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Reshma Rangwala files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Richard A. Paulson - $137K in KPTI purchases and sales in the last 12 months
- Stuart Poulton - $56K in KPTI purchases and sales in the last 12 months
- Sohanya Roshan Cheng - $46K in KPTI purchases and sales in the last 12 months
- Michael Mano - $36K in KPTI purchases and sales in the last 12 months
- Lori Macomber - $10K in KPTI purchases and sales in the last 12 months
- Kristin Abate - $8K in KPTI purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Reshma Rangwala?
Reshma Rangwala is a corporate insider, tracked as EVP & Chief Medical Officer of Karyopharm Therapeutics Inc. (KPTI). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Reshma Rangwala last file a Form 4?
The most recent primary Form 4 on record is dated 15 May 2026, one of 5 filings going back to 2025.
Has Reshma Rangwala been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($58K) across all tracked filings.
